Tags : Onstryv

Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson’s

Tuba Khan July 12, 2019

Shots: The launch of Onstryv follows its Health Canada approval received on Jan 15, 2019 as an add-on therapy to a levodopa regimen indicated to treat signs and symptoms of […]readmore

Tags : Onstryv

Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson’s

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Onstryv

Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson’s

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company